Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type 2 selected

Type

Guidance programme 11 selected

Guidance programme

Showing 41 to 50 of 1244

TitleReference numberPublishedLast updated
Sparsentan for treating primary IgA nephropathyTA1074
Garadacimab for preventing recurrent attacks of hereditary angioedema in people 12 years and overTA1101
Durvalumab for treating limited-stage small-cell lung cancer after platinum-based chemoradiotherapyTA1099
Mirabegron for treating neurogenic detrusor overactivity in people 3 to 17 years (terminated appraisal)TA1100
HIV testing: increasing uptake among people who may have undiagnosed HIVNG60
Isatuximab in combination for untreated multiple myeloma when a stem cell transplant is unsuitableTA1098
Atopic eczema in under 12s: diagnosis and managementCG57
Enfortumab vedotin with pembrolizumab for untreated unresectable or metastatic urothelial cancer when platinum-based chemotherapy is suitableTA1097
Chronic heart failure in adults: diagnosis and managementNG106
Benralizumab for treating relapsing or refractory eosinophilic granulomatosis with polyangiitisTA1096

Results per page

  1. 10
  2. 25
  3. 50
  4. All